Induction of Plasminogen Activator Inhibitor by Products Released From Platelets
Satoshi Fujii, MD, and Burton E. Sobel, MD Activation of platelets and augmentation of plasma plasminogen activator inhibitor (PAI) type activity accompany acute myocardial infarction. To determine whether the two may be related, platelet compounds including epidermal growth factor and transforming growth factor as well as platelet lysates were studied in rabbits in vivo. After intravenous infusion of epidermal growth factor (1 and 5 ug/kg), plasma PAI activity increased sevenfold and 20-fold, peaking at 2 hours. After infusions of transforming growth factor P3 (0.2 and 0.5 ,ug/kg), plasma PAI activity increased sevenfold and 12-fold but peaked more slowly (at 5 hours). After infusion of platelet lysates (lysates from 2.8 and 5.6x108 platelets/kg), the increase was 19-fold and 35-fold, with a peak at 4 hours. Platelet lysates induced a pronounced increase of plasma PAI type 1 messenger RNA (Northern blots) in aorta, liver, and myocardium. Anti-transforming growth factor ,B neutralizing antibody markedly attenuated the plasma PAI increase. Concentrations in plasma of fibrinogen and ca2-antiplasmin were virtually unaffected under all conditions. Thus, platelet-associated growth factors and platelet lysates, shown previously to increase plasma PAI type 1 messenger RNA expression and protein production in cultured hepatocytes and vascular endothelial cells in vitro, augment plasma PAI in vivo as well. Accordingly, activation of platelets and release of platelet-associated growth factors appear to contribute to the increased plasma PAI seen after myocardial infarction. (Circulation 1990; 82:1485 -1493 T he efficacy of pharmacological coronary thrombolysis appears to depend on the relative intensity of fibrirnolysis and thrombosis in the immediate vicinity of targeted thrombi.'-4 Local fibrinolysis, mediated in part by plasminogen activators elaborated from endothelium as well as activator administered pharmacologically, may be attenuated by inhibitors including a2-antiplasmin and plasma plasminogen activator inhibitor (PAI) type 1 (PAL-1). 5, 6 Increases in plasma PAI activity have been implicated as a risk factor for myocardial infarction.7, 8 We recently found that plasma PAI-1 messenger RNA (mRNA) levels and protein synthesis9'10 in cultured human hepatocytes are augmented by platelet-associated growth factors including epidermal growth factor (EGF) and transforming growth factor ,B (TGF-/3), and by crude platelet lysates. Others have reported increases in PAI-1 mRNA in cultured bovine aortic endothelial cells." In view of
From the Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri. Supported in part by National Institutes of Health grant HL-17646, SCOR in Ischemic Heart Disease. the high concentrations of platelet products within thrombi (approximately 200-fold greater than the concentrations in whole blood'2), we have hypothesized that platelet products may attenuate fibrinolysis in vivo by augmenting endothelial cell synthesis and release of plasma PAI locally in the vicinity of thrombi, and hepatic elaboration of PAI-1 into the circulation.' Such attenuation could potentially be modified with the use of plasma PAI-1 invisible mutants of plasminogen activators13 and by conjoint use of antiplatelet and fibrinolytic drugs. The present study was performed to determine whether our previous observations with hepatocytes in vitro were applicable in rabbits in vivo and to determine whether platelet lysates induced increased concentrations of plasma PAI. Additionally, it addressed mechanisms by which platelet activation may affect PAI concentrations in plasma in vivo in studies using antibodies to specific growth factors released.
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Preparation of Platelet Lysates
Platelets were isolated from rabbit platelet-rich plasma as previously described.10 Lysates were prepared by freezing in liquid nitrogen and thawinig in a 370 C water bath three times. Supernatant fractions were stored at -70°C for 1 week and thawed once for infusion of platelet lysates intravenously in the same platelet-donor rabbit. Lysate obtained from 108 platelets inhibited 0.53+0.07 IU/ml t-PA (mean±SD, n = 6). Inhibitory effects were linearly related to platelet lysate concentration. The absence of endotoxin in platelet lysate preparations was confirmed with the limulus amebocyte lysate assay (Pyrotell, Associates of Cape Cod, Woods Hole, Massachusetts).
Procedures in Experimental Animals
Care and handling of experimental animals conformed to the standards established by the Washington University Committee for Humane Care of Laboratory Animals consistent with those of the Helsinki declaration. New Zealand White rabbits (2.5-3.3 kg body wt) were supplied by the Boswell Bunny Farm (St. Louis, Missouri). Rabbits were anesthetized with intramuscular injection of 0.1 ml of Inovar-Vet (0.4 mg/ml fentanyl and 20 mg/ml droperidol) and ketamine (20 mg/kg) in dosages sufficient to maintain analgesia and anesthesia. Subsequently, intravenous bolus injections of pentobarbital were administered as needed to maintain adequate analgesia and anesthesia. Growth factors and platelet lysates were administered through an external jugular vein catheter. For acquisition of plasma samples, whole blood was collected from an external jugular vein or femoral artery catheter with a two-syringe technique in plastic syringes and transferred immediately into tubes maintained at 0-4°C containing sodium citrate (12.9 mM final concentration) as previously described.22 Catheters were flushed with 3 ml sterile saline after acquisition of each sample. Plasma samples were separated quickly by centrifugation at 40 C at 2,000g for 15 minutes, aliquots were frozen immediately in liquid nitrogen, and samples were stored at -70°C for subsequent assay. Samples for assay of fibrinogen were collected in citrate tubes with PPACK (2 gM). All assays were performed within 1 week.
Blood leukocyte and platelet counts were determined conventionally with a hemocytometer.
Pharmacokinetic Studies
Rabbits were given [251I]EGF (6.1 ng/kg) or ['25I]TGF-f3 (4.9 ng/kg) in 0.5-ml aliquots of phosphate-buffered saline by intravenous bolus injection through the femoral vein. All rabbits were pretreated with 100 mg Nal injected intraperitoneally 10 minutes before injection of growth factor to block thyroidal uptake of released radioactive iodide. Serial blood samples were obtained at selected intervals by the femoral artery into sodium citrate tubes and centrifuged to yield plasma samples (500 ,ul) that were supplemented with trichloroacetic acid (20% wt/vol) for precipitation of protein at 0-4°C. Precipitates were assayed for 1251 radioactivity in a gamma well counter to provide estimates of the concentration of each of the growth factors in plasma as a function of time Nuclear, Wilmington, Delaware). Blots were baked at 800 C for 2 hours in a vacuum, and hybridization was performed conventionally.9 Briefly, membranes were prehybridized in a solution of 50% deionized formamide, x 10 Denhardt's solution, 0.05 M TrisHCl, 1.0 M NaCl, 0.1% sodium pyrophosphate, 1% SDS, 10% dextran sulfate, and 100 ,ug/ml sonicated denatured salmon sperm DNA for at least 6 hours at 420 C with agitation.
Hybridization with 320,000 dpm/ml PAI-1 and 160,000 dpm/ml GAP of labeled probe was performed at 420 C for 20-24 hours. After hybridization, membranes were washed three times for 20 minutes each at 550 C with 1% SDS and 2x, lx, and 0.5x SSC (1 x SSC=0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), respectively. Blots were assayed with a radioisotopic scanner (Ambis Radioisotope Scanner, Automated Microbiology System, San Diego, California) for quantification of radioactivity corresponding to each band. Hybridization to the GAP probe was used as an internal control to ensure consistent quantity and integrity of RNA samples present on the blot after transfer and hybridization.
Autoradiography was performed with Kodak XAR-5 film and intensifying screens (Cronex lightning plus, DuPont-New England Nuclear) at -70°C. The size, in kilobases, of detected mRNA species was calculated on the basis of migration of DNA standards from the gel wells.
Statistical Analysis
Results are presented as mean+SD of the mean. Repeated measures analysis of variance was used to assess changes in physiological variables over time. A p value less than or equal to 0.05 was considered indicative of a significant difference.
Results

Effect of Growth Factors and Platelet Lysates on Plasma PAI-1 Activity In Vivo
An early increase in plasma PAI activity (p<0.05) was evident within 1 hour in rabbits given EGF (Figure 1 , upper left panel), with a peak in 2 hours and subsequent rapid decline. The plasma PAI levels were significantly elevated above baseline up to 4 hours after administration in the group of rabbits receiving 1 gg/kg and up to 6 hours in the group of rabbits receiving 5 ug/kg. Increases were greater with 5 gg/kg than with 1 ,ug/kg doses of EGF. When EGF (1 jig/kg) was neutralized with anti-EGF antibody before injection, no significant changes in plasma PAI activity ensued.
In rabbits given TGF-,8 (0.2 or 0.5 ,ug/kg), PAI activity in plasma was significantly increased after 2 hours. In comparison with the response to EGF, however, the time course of the increase differed, with a peak in 5 hours and a gradual decline subsequently ( Figure 1, upper right panel) . The plasma PAI levels were significantly elevated above baseline up to 6 hours after administration in the groups of rabbits receiving both 0.2 and 0.5 ,ug/kg. To determine whether platelet lysates increased PAI activity in plasma, autologous platelet lysates prepared 1 week before the experiment were given intravenously to rabbits (lysates from 2.8 or 5.6 x 108 platelets/kg body wt). Plasma PAI activity increased significantly from 2 to 6 hours after administration in the group of rabbits receiving 2.8 x 108/kg and from 1 to 6 hours in the group of rabbits receiving 5.6x 108/ kg. The peak effect was observed at 3-4 hours. Activity remained elevated to 45-55% of peak activity after 6 hours ( Figure 1, lower panel) . Increases were significantly greater with the more concentrated lysates. Infusion of platelet-poor plasma had no significant effect on plasma PAI activity. When platelet lysates were pretreated with anti-TGF-/3 neutralizing antibody, plasma PAI levels were still significantly elevated above baseline from 2 to 6 hours after administration. Stimulatory effect of lysates on plasma PAI activity, however, were markedly attenuated. Thus, after 2 hours, the magnitude and duration of plasma PAI increase was significantly reduced compared with values in rabbits given lysates that had not been neutralized with antibody to TGF-,8 ( Figure   1, lower panel) . Accordingly, one of the components in lysates responsible for augmentation of plasma PAI activity appeared to be TGF-f3. In contrast, when 2.8x 108/kg platelet lysates were pretreated with anti-EGF neutralizing antibody, the initial increases of PAI activity in plasma were not attenuated at all (n=2, data not shown).
Assays of plasma PAI-1 antigen concentrations with an enzyme-linked immunosorbent assay (ELISA) developed for human plasma PAI-1 correlated closely with plasma PAI activity (r=0.94, n=56). The increases of plasma PAI activity were demonstrable also by reverse fibrin autography after SDS-PAGE of plasma samples (data not shown). (Figure 2 ). In the distribution phase after intravenous bolus injections, both growth (EGF) and 37.2 minutes (TGF-f,).
High concentrations of 1251-labeled EGF and TGF-, / after intravenous bolus injection were found in kidney, liver, spleen (Figure 2 ), and lung, in which the concentration of TGF-f3 was maximal. Concentrations in these organs were 20-70-fold greater than in blood (radioactivity/g). Thus, tissue concentrations could not be explained simply by trapping of blood, especially after the extensive rinsing used. Tissues demonstrat- Whole organ distribution patterns were calculated based on organ weights and total blood volumes. Liver and kidney accumulated approximately 90% of the total injected dose of EGF (Figure 3) . Liver, lung, and kidney accumulated approximately 70% of the total injected doses of TGF-,8 ( Figure 3) .
To verify the lack of degradation of injected labeled TGF-,6, plasma obtained 5 minutes after 
Effect of Platelet Lysates on Expression of PAI-1
Messenger RNA in Rabbit Tissues In Vivo As previously reported, PAI-1 mRNA in human tissues appears as 3.2 and 2.2 kb species in different proportions typical of different tissues.9 In the present studies, however, only one PAI-1 mRNA species (3.2 kb) was detectable in extracts from rabbit tissues even with replicated Northern blots subjected to stringent conditions.
In rabbits given platelet lysates, PAI-1 mRNA levels were increased (three-to fivefold) in aorta and heart as well as in liver (Figure 4) (n=3) . No increases were seen in lung, kidney, spleen, or muscle. The apparent concentration (control) of GAP mRNA did not change (Figure 4 ).
Discussion
Results of this study indicate that platelet lysates increase PAI activity in rabbit plasma in vivo and PAI1 mRNA in aorta, liver, and heart. Additionally.
platelet lysates augment plasma PAI-1 protein in conditioned media and PAI-1 mRNA in cultured cells."' Thus, it appears likely that platelet activation associated with phenomena such as coronary thrombosis and coronary thrombolysis in vivo may augment plasma PAI-1 locally, thereby attenuating fibrinolysis mediated by endogenous plasminogen activators and exogenous agents such as t-PA. The increases in plasma PAI activity in vivo were seen with plasma concentrations of EGF, TGF-3, and platelet lysates that did not markedly influence concentrations of a2-antiplasmin or fibrinogen, and that were consistent with physiological levels and those anticipated after myocardial infaretion. Thus, although plasma PAL-1 increases rapidly after surgery or trauma,3' the changes we observed cannot be explained simply in terms of an acute phase reaction.
PAI in plasma appears to be identical to that produced by endothelial cells.3233 The increased plasma PAL activity we observed, paralleled by an increase in plasma PAI-1 antigen, could reflect release of PAI from platelets,34 increased release from endothelium, hepatocytes, or other tissue, or both. Release of PAI-I from platelets was probably not pivotal because 1) platelet counts did not decline, 2) platelets in citrated platelet-rich plasma did not aggregate in response to EGE (up to 100 ng/ml) or TGF-f3 (up to 100 ng/ml) (unpublished observations), 3) high concentrations of thrombin capable of inducing more than a 50% decline in platelet counts do not augment PAI activity in plasma35 and 4) much of the inhibitor present in platelets may be inactive or latent. 16 As judged from the changes in concentrations of PAI-1 mRNA in tissues, it appears likely that endothelial cells and hepatocytes are responsible for the increases in PAI activity in plasma induced by platelet lysates in vivo. This hypothesis is consistent with our observations in cultured cells demonstrating increased elaboration of PAI-1 in response to platelet lysates in association with an increase in steadystate levels of PAI-I mRNA.
Activity of growth factors used in the present study is present in human platelets.36 ' be cleared with a half-life of approximately 30 minutes, in quantities sufficient to increase PAI-1 mRNA in hepatocytes. The activity of PAI in human platelets is an order of magnitude greater than that in rabbit platelets.42 Accordingly, in fresh human thrombi, the concentration of PAI may be even higher because of release from platelets participating in clotting. The presence of platelet-derived PAI and the effects of factors from platelets leading to increased PAI synthesis may both contribute to resistance of platelet-rich thrombi to plasminogen activators.
The present results are consistent with the hypothesis that platelet-released growth factors may augment PAI-1 concentrations locally and in the circulation, thereby attenuating coronary thrombolysis and potentially limiting its efficacy by retarding recanalization or predisposing to early reocclusion. Accumulation of platelets at sites of endothelial injury and their consequent release of growth factors may explain the high concentrations of TGF-J3 found in coronary thrombi.43 These phenomena are particularly promising targets for adjunctive pharmacological approaches to potentiation of coronary thrombolysis with antiplatelet drugs, antibodies, or neutralizing F(ab')2 fragments directed against circulating or locally released growth factors, and inhibitor-invisible plasminogen activators. Our results are consistent also with the possibility that some of the beneficial effects of antiplatelet agents in patients treated with plasminogen activators such as t-PA may reflect diminished stimulation of synthesis of PAI-1.
